Lanton Law Blog — Lanton Law

House Passes the MORE Act

The House of Representatives passed the Marijuana Opportunity Reinvestment and Expengement Act of 2020 otherwise known as the MORE Act of 2020 or H.R. 3884. The party line vote was 228 to 164. The bill proposes to remove cannabis from the Controlled Substance Act and seeks to mirror the changing policy around this subject as medical cannabis is legal in ⅔ of the states while approximately 15 states have passed laws permitting recreational usage. The bill heads to the Senate where it is not expected to pass this session.

cannabis, CBD, Congress, medical marijuana, pharmaceuticals, pharmacy, marijuanaRon LantonDecember 8, 2020MORE Act of 2020, Marijuana Opportunity Reinvestment and Expengement Act of 2020, H.R. 3884, medical cannabis, cannabis

Psychedelic mushrooms take a policy step forward

In what has surprised many cannabis stakeholders it seems as though the November 2020 elections is bringing a new therapeutic item into the mainstream healthcare policy conversation: psychedelic mushrooms via ballot box initiatives.

cannabis, CBD, healthcare, medical marijuana, pharmaceuticals, pharmacy, psychedelic mushroomsRon LantonNovember 7, 2020psychedelic mushrooms, ballot initiative, District of Columbia, Measure 110, Measure 109, Initiative 81, Oregon

November Election Yields Gains for Marijuana Legalization

The result of a few November 3, 2020 election ballot measures have yielded additional gains for marijuana.

cannabis, CBD, healthcare, legislation, medical marijuanaRon LantonNovember 4, 2020cannabis, medical marijuana, recreational marijuana, Arizona, South Dakota, Mississippi, New Jersey

Lanton Law Opens Cannabis Practice

Lanton Law believes that the cannabis market will continue to evolve and expand. Notwithstanding this market potential is the fact that medical and adult-use cannabis operations are confronted with a complex patchwork of state and federal laws and regulations that we assist a variety of businesses with.

cannabis, CBD, FDA, FTC, healthcare, banking, medical marijuana, pharmaceuticals, pharmacy, USDARon LantonOctober 9, 2020cannabis, CBD, marijuana, medical marijuana, regulation, dispensary, recreational marijuana, adult-use marijuana

FDA Cannabis Draft Guidance Comment Period Closes

On September 21st the FDA closed its comment period related to cannabis. Back in July the Food and Drug Administration (FDA) announced the availability of a draft guidance for industry entitled “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research.”

cannabis, CBD, FDA, government affairs, healthcare, HHS, life sciences, clinical researchRon LantonSeptember 27, 2020FDA, cannabis, CBD, FDA guidance